NASDAQ:ATHX - Athersys Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 414.29 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.75
▲ +0.02 (1.16%)
1 month | 3 months | 12 months
Get New Athersys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATHX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATHX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.00
▲ +414.29% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Athersys in the last 3 months. The average price target is $9.00, with a high forecast of $14.00 and a low forecast of $5.00. The average price target represents a 414.29% upside from the last price of $1.75.
Buy
The current consensus among 4 investment analysts is to buy stock in Athersys. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2020Needham & Company LLCReiterated RatingBuy$5.00High
i
10/12/2020Dawson JamesReiterated RatingBuyLow
i
8/11/2020Needham & Company LLCReiterated RatingBuy$5.00High
i
6/25/2020Bank of AmericaInitiated CoverageBuy$5.00High
i
5/8/2020Needham & Company LLCLower Price TargetBuy$6.00 ➝ $5.00Low
i
5/6/2020Dawson JamesReiterated RatingBuy$12.00Low
i
4/23/2020Smith Barney CitigroupInitiated CoverageOutperform$14.00Low
i
8/26/2019Dawson JamesInitiated CoverageBuy$11.00High
i
5/9/2019Maxim GroupReiterated RatingBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
1/23/2019Maxim GroupSet Price TargetBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
8/8/2018Maxim GroupReiterated RatingBuy$6.00High
i
Rating by Jason McCarthy at Maxim Group
7/31/2018Maxim GroupReiterated RatingBuy$6.00High
i
Rating by Jason McCarthy at Maxim Group
5/11/2018Maxim GroupSet Price TargetBuy$6.00Low
i
Rating by Jason McCarthy at Maxim Group
4/23/2018Maxim GroupInitiated CoverageBuy$6.00Medium
i
Rating by Jason McCarthy at Maxim Group
3/13/2018Maxim GroupReiterated RatingBuy$6.00High
i
Rating by Jason Kolbert at Maxim Group
2/13/2018Maxim GroupSet Price TargetBuy ➝ Buy$12.00 ➝ $6.00Medium
i
Rating by Jason Kolbert at Maxim Group
11/16/2017Maxim GroupSet Price TargetBuy$12.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/5/2017Maxim GroupSet Price TargetBuy$12.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/1/2017Maxim GroupReiterated RatingBuy$12.00High
i
Rating by Jason Kolbert at Maxim Group
8/7/2017Maxim GroupSet Price TargetBuy ➝ Buy$9.00 ➝ $12.00High
i
Rating by Jason Kolbert at Maxim Group
5/16/2017Maxim GroupSet Price TargetBuy$9.00Medium
i
Rating by Jason Kolbert at Maxim Group
5/10/2017Maxim GroupReiterated RatingBuyHigh
i
Rating by Jason Kolbert at Maxim Group
3/28/2017William BlairReiterated RatingOutperformHigh
i
Rating by Y. Xu at William Blair
3/20/2017Maxim GroupSet Price TargetBuy$9.00High
i
Rating by Jason Kolbert at Maxim Group
3/11/2017Maxim GroupSet Price TargetBuy$9.00Medium
i
Rating by Jason Kolbert at Maxim Group
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00N/A
i
11/12/2016Maxim GroupSet Price TargetBuy$10.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/28/2016Maxim GroupReiterated RatingBuy$10.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/12/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
6/27/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
5/8/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 4/22/2016 forward)
Athersys logo
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Read More

Today's Range

Now: $1.75
$1.70
$1.75

50 Day Range

MA: $1.82
$1.61
$2.02

52 Week Range

Now: $1.75
$1.53
$3.39

Volume

13,386 shs

Average Volume

3,049,728 shs

Market Capitalization

$380.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Athersys?

The following Wall Street analysts have issued research reports on Athersys in the last twelve months: Bank of America Co., Dawson James, Needham & Company LLC, Smith Barney Citigroup, and Zacks Investment Research.
View the latest analyst ratings for ATHX.

What is the current price target for Athersys?

4 Wall Street analysts have set twelve-month price targets for Athersys in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 414.3%. Smith Barney Citigroup has the highest price target set, predicting ATHX will reach $14.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $5.00 for Athersys in the next year.
View the latest price targets for ATHX.

What is the current consensus analyst rating for Athersys?

Athersys currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATHX will outperform the market and that investors should add to their positions of Athersys.
View the latest ratings for ATHX.

What other companies compete with Athersys?

How do I contact Athersys' investor relations team?

Athersys' physical mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company's listed phone number is 216-431-9900 and its investor relations email address is [email protected] The official website for Athersys is www.athersys.com.